|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ALXN 8-K filed Nov 23, 2005. Item 7.01 Regulation FD Disclosure.
On November 23, 2005, Alexion Pharmaceuticals, Inc. issued a press release relating to results from its Phase III PRIMO-CABG2 clinical trial with pexelizumab. A copy of the press release is furnished as Exhibit 99.1 to this form 8-K.
|
| |||||||